



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C07J 71/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/11280</b> <b>(43) International Publication Date:</b> 9 July 1992 (09.07.92)
<b>(21) International Application Number:</b> PCT/PL91/00016 <b>(22) International Filing Date:</b> 17 December 1991 (17.12.91)  <b>(30) Priority data:</b> P-288360 20 December 1990 (20.12.90) PL  <b>(71) Applicant:</b> INSTYTUT FARMACEUTYCZNY [PL/PL]; ul. Rydygiera 8, 01-793 Warszawa (PL).  <b>(72) Inventors:</b> USZYCKA-HORAWA, Teresa ; ul. Etiudy Re- wolucyjnej 5/7 m 72, 02-643 Warszawa (PL). SMOLINS- KA, Jadwiga ; pl. Wilsona 4 m 89, 01-626 Warszawa (PL). KROSZCZYNSKI, Wojciech ; ul. Potocka 6 m 76, 01-652 Warszawa (PL).		<b>(81) Designated States:</b> AT (European patent), BE (European patent), BR, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD OF OBTAINING (22R) DIASTEREOMER OF BUDESONIDE  <b>(57) Abstract</b>  By the method according to the invention condensation of 11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 21-acetate with n-butyric aldehyde is carried out, in the known way, in the medium of hydrofluoric acid of concentration of 70-80 %. The isolated crude condensation product is crystallized from ethanol and obtained 21-acetate of budesonide (22R) of at least 95 % content is hydrolyzed, and the product thus obtained is crystallized from ethyl acetate.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE <sup>+</sup>	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

**Method of obtaining (22R) diastereoisomer of budesonide**

The subject of the invention is a method of obtaining diastereoisomer of (22R) budesonide. Budesonide, i.e. (22R,S)-16 $\alpha$ ,17 $\alpha$ -butylidenedioxy-11 $\beta$ ,21-dihydroxy-1,4-pregnadiene-3,20-dione is a mixture of diastereoisomers (22R) and (22S) differing in the position of an acetal chain (fig.1 and 2). Both compounds are active glucocorticoids applied in a mixture (1:1) in pharmaceutical forms: antiasthmatic aerosol or antiallergic ointment. (22R) diastereoisomer is 2-3 times more active pharmacologically than (22S) diastereoisomer [Brattsand R.; Eur.J.Res.Dis.63, suppl. 122,62-73 (1982)].

In pharmacotherapy a tendency is presently observed to apply optically active compounds and not racemic mixtures. In the case of budesonide both isomeric forms are pharmacologically active but their metabolism is different [Andersson P. et al.; Xenobiotica 17,35-44 (1987)]. Testing of action of a drug being a pure chemical individual is considerably easier than that of a mixture.

A known method of obtaining budesonide, that is a mixture of diastereoisomers (22R) and (22S) consists in condensation of 11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrahydroxy-1,4-pregnadien-3,20-dione with n-butyric aldehyde in the presence of strong inorganic acids, e.g. perchloric acid, in organic solvents [FRG patent 2323216(1973)].

Those skilled in the art know also a method of obtaining a mixture of diastereoisomers (22R) and (22S), in which isomer (22R) is in majority, even up to 90%. The said method consists in condensation, discussed above, conducted in the presence of hydrofluoric acid of concentration of 48-70% or concentrated hydrochloric acid [Eur.pat.appln.164636 (28.05.85)].

According to the known method separation of a mixture of diastereoisomers (22R) and (22S) is carried out on a

- 2 -

column packed with Sephadex LH20 [Thalen A., Nylander B.; 19,247-266(1982)]. The said method requires the use of a very big amount of solvents and long separation time, and for these reasons it is technologically inconvenient, 5 expensive and time-consuming.

Unexpectedly it has appeared out that the product obtained after condensation in the form of 21-acetate containing at least 80% of diastereoisomer (22R), after crystallization from ethanol, and then hydrolyzed and 10 crystallized from ethyl acetate yields pure diastereoisomer (22R) with an admixture of diastereoisomer (22S) of 1% at the very most. The content of diastereoisomers is determined by the HPLC method. From post-crystallization filtrates containing a mixture 15 of diastereoisomers of a composition of 8:2 or 7:3 one may separate budesonide 21-acetate, crystallize it again and after hydrolysis obtain pure diastereoisomer (22R).

By the method according to the invention condensation of 11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 20 21-acetate with n-butyric aldehyde is carried out, in the known way, in the medium of hydrofluoric acid of concentration of 70-80%. The isolated crude condensation product is crystallized from ethanol and obtained 21-acetate of budesonide (22R) of at least 95% content is 25 hydrolyzed, and the product thus obtained is crystallized from ethyl acetate to obtain (22R) diastereoisomer of budesonide of at least 99% content.

An advantageous effect of the invention is that (22R) diastereoisomer of budesonide having the content of at 30 least 99% is obtained at a yield of about 60%. The product obtained by the method according to the invention is an active substance of antiasthmatic aerosol and its content in a dose of 158  $\mu$ g is equivalent to 200  $\mu$ g of budesonide of a mixture (1:1) of diastereoisomers (22R 35 and 22S). The method according to the invention is characterized by simplicity of procedure, enables saving organic solvents and is less labour-consuming.

- 3 -

The after-mentioned example illustrates the invention without limiting its scope.

Example.

To a mixture of 7 ml of 75% hydrofluoric acid and 5 0.52 ml of n-butyric aldehyde, cooled to 0°C, 3.5 g of 11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 21-acetate is added in and stirred for 3 hours at maintenance of the temperature of 0°C. The obtained dark-red solution is poured into 50 ml of water with ice, 10 neutralized by concentrated ammonia and extracted by chloroform. From the extract chloroform is distilled off under diminished pressure, and the residue is crystallized from ethanol. 2.2 g of 21-acetate of (22R) diastereoisomer of budesonide of  $[\alpha]_D^{22} +106^\circ$  (c=1, CH<sub>2</sub>Cl<sub>2</sub>) 15 is obtained, the content of 21-acetate of (22S) diastereoisomer of budesonide is 5%. The product is suspended in 40 ml of methanol, cooled to 0°C, 2.5 ml of 10% aquas solution of potassium carbonate is added thereto, and is stirred under nitrogen for 1 and 1/2 20 hours, at maintenance of the temperature of 0°C, after this it is neutralized with acetic acid, methanol is evaporated and (22R) diastereoisomer of budesonide is isolated either by filtering off or by extraction with chloroform. The separated product is crystallized from 25 ethyl acetate and 1.7 g of (22R) diastereoisomer of budesonide is obtained, of melting point of 245-250°C (decomp.)  $[\alpha]_D^{22} +117.5^\circ$  (c=1, CH<sub>2</sub>Cl<sub>2</sub>);  $a_{1\text{cm}}^{1\%}$  350 at 242 nm. The content of (22S) diastereoisomer of budesonide determined by the the HPLC method is 1%.

- 4 -

## Patent claim

Method of obtaining of (22R) diastereoisomer of  
budesonide, consisting in a condensation reaction of  
5 11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetra-hydroxy-1,4-pregnadiene-3,20-dione  
21-acetate with n-butyric aldehyde conducted in the  
medium of hydrofluoric acid of concentration of 70-80%,  
characterized in that the isolated crude product of  
condensation is crystallized from ethanol and obtained  
10 21-acetate of budesonide (22R) of at least 95% content is  
hydrolyzed, and the product thus obtained is crystallized  
from ethyl acetate.

- 1/1 -




Fig. 1




Fig. 2

## INTERNATIONAL SEARCH REPORT

PCT/PL 91/00016

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07J71/00		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C07J	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP,A,0 164 636 (SICOR SOCIETA ITALIANA CORTICOSTEROIDI S.P.A.) 18 December 1985 cited in the application see page 8; example 1	1
A	US,A,3 996 359 (AB BOFORS) 7 December 1976 see the whole document	1
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
16 MARCH 1992	24. 03. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	WATCHORN P.W. <i>Peter Watchorn</i>	



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PL 9100016  
SA 54730**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 16/03/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0164636	18-12-85	JP-C- 1588637	19-11-90
		JP-B- 2013680	04-04-90
		JP-A- 61040299	26-02-86
		US-A- 4835145	30-05-89
		US-A- 4695625	22-09-87
US-A-3996359	07-12-76	SE-B- 378110	18-08-75
		AU-A- 5525273	07-11-74
		BE-A- 799728	17-09-73
		CA-A- 1003402	11-01-77
		DE-A, C 2323216	29-11-73
		FR-A, B 2185406	04-01-74
		GB-A- 1428416	17-03-76
		JP-C- 975395	19-10-79
		JP-A- 49041379	18-04-74
		JP-B- 54007794	10-04-79
		NL-A- 7306979	21-11-73
		US-A- 3928326	23-12-75
		US-A- 3992534	16-11-76